Pharmaceutical Development
With more than 30 years of specialization in the field of solid dosage forms, you can expect more from Siegfried. We provide a broad range of pharmaceutical development services to suit your needs. Siegfried’s projects range from products that require difficult formulation, to demanding narcotic or high potency active pharmaceutical ingredients (API), on through to developing robust manufacturing processes and application of new leading technologies. Additionally, we are well experienced in developing second and third generation formulations to support product life-cycle management.
Whether your product is in early or late stage, if you need a fresh creative approach, you can expect more from Siegfried to help realize your goal.
Our Drug Product Development Department consists of two groups based at our Zofingen site in Switzerland: Pharmaceutical Development and Analytical Development. Using leading modern equipment & instrumentation we are well-suited for developing a range of solid dosage forms.
To give an idea of the range of projects that we work on, some examples from our many completed projects include:
- Tablets using very unstable APIs
- Rapid release tablets for poorly soluble APIs
- Hard capsules with delayed release (pellets, minitablets)
- Matrix tablets with delayed release
- Oral disintegrating tablets (ODT) and chewable tablets
Our Galenic Group provides sound technical knowledge and experience in the development of solid dosage forms, ranging from simple powder mixtures up to complex formulations (e.g., with delayed release). The Galenic Lab is well-equipped to cover the entire scope of services, from early phase development (e.g., active pharmaceutical ingredient (API) sourcing and characterization, compatibility studies) up to commercial manufacturing. We consider the lab to be the cornerstone of our top quality formulation services.
Besides processing your own active ingredients, we can also provide you with the technical knowledge and support of our Drug Substance custom development & manufacturing, which develops those actives for you. One of the many benefits this brings is that the API specifications are pre-determined in early phase, providing harmonization with the formulation required.
Siegfried is currently expanding its services by considering hot-melt extrusion, gastro-retentive formulations, and others. For early development phases, we also offer development of other administration forms (e.g., injection preparations, eye drops, etc.) under non-GMP conditions.
Likewise, the development and manufacture of solid dosage forms is offered for high potency APIs (for materials with occupational exposure limits of 1-10µg/m³) in a new area specifically built for handling highly-active substances (to cGMP).
Additionally, in tandem with Siegfried’s strengths in supply of narcotic controlled substances, we are also able to offer development and manufacture of clinical samples involving narcotic ingredients (BTM approval).